P
Pharmix
Innovative pharmaceutical solutions specializing in high-quality tablets, injections, and infusions for diverse medical needs
About Pharmix
Pharmix is a pharmaceutical company dedicated to developing and manufacturing a wide range of high-quality medical products, including tablets, injections, and infusions. The company serves healthcare providers, hospitals, and clinics, primarily in the Asian market. Pharmix operates on a B2B (business-to-business) model, generating revenue through the sale of its pharmaceutical products to medical institutions and distributors. The company focuses on ensuring the efficacy and safety of its products, adhering to stringent quality control measures. Key offerings include Citicoline tablets and injections, Dexamethasone injections, Dextrose infusions, and various other specialized medications.
Source: Dealroom company dataAt a glance
- Founded
- 1994
- Headquarters
- South Korea
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Mohr Davidow Ventures
Latterell Venture Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Pharmix on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Pharmix on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.